BIOMAT Database Logo BIOMAT Database Logo

Failure of immunotherapy with neuraminidase-treated tumor cell vaccine in mice bearing established 3-methylcholanthrene-induced sarcomas. 1978

R J Spence, and R M Simon, and A R Baker

C3H/HeJ mice bearing MC-80 fibrosarcomas were given immunotherapy consisting of multiple injections of a Vibrio cholerae neuraminidase (VCN)-treated tumor cell vaccine at a site remote from the established tumor. In five separate experiments we were unable to show either partial or complete tumor regression or prolongation of survival for vaccine-treated mice compared to appropriate controls. Further, the use of BCG in addition to VCN-treated tumor cells failed to show any therapeutic efficacy. We could not confirm the successful immunotherapy results reported by others despite multiple efforts of reproduce the immunotherapy model as carefully and precisely as possible.

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D008748 Methylcholanthrene A carcinogen that is often used in experimental cancer studies. 20-Methylcholanthrene,3-Methylcholanthrene,20 Methylcholanthrene,3 Methylcholanthrene
D008809 Mice, Inbred C3H An inbred strain of mouse that is used as a general purpose strain in a wide variety of RESEARCH areas including CANCER; INFECTIOUS DISEASES; sensorineural, and cardiovascular biology research. Mice, C3H,Mouse, C3H,Mouse, Inbred C3H,C3H Mice,C3H Mice, Inbred,C3H Mouse,C3H Mouse, Inbred,Inbred C3H Mice,Inbred C3H Mouse
D008937 Mitomycins A group of methylazirinopyrroloindolediones obtained from certain Streptomyces strains. They are very toxic antibiotics used as ANTINEOPLASTIC AGENTS in some solid tumors. PORFIROMYCIN and MITOMYCIN are the most useful members of the group.
D009439 Neuraminidase An enzyme that catalyzes the hydrolysis of alpha-2,3, alpha-2,6-, and alpha-2,8-glycosidic linkages (at a decreasing rate, respectively) of terminal sialic residues in oligosaccharides, glycoproteins, glycolipids, colominic acid, and synthetic substrate. (From Enzyme Nomenclature, 1992) Sialidase,Exo-alpha-Sialidase,N-Acylneuraminate Glycohydrolases,Oligosaccharide Sialidase,Exo alpha Sialidase,Glycohydrolases, N-Acylneuraminate,N Acylneuraminate Glycohydrolases,Sialidase, Oligosaccharide
D002452 Cell Count The number of CELLS of a specific kind, usually measured per unit volume or area of sample. Cell Density,Cell Number,Cell Counts,Cell Densities,Cell Numbers,Count, Cell,Counts, Cell,Densities, Cell,Density, Cell,Number, Cell,Numbers, Cell
D005260 Female Females
D005354 Fibrosarcoma A sarcoma derived from deep fibrous tissue, characterized by bundles of immature proliferating fibroblasts with variable collagen formation, which tends to invade locally and metastasize by the bloodstream. (Stedman, 25th ed) Fibrosarcomas
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000951 Antigens, Neoplasm Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin. Neoplasm Antigens,Tumor Antigen,Tumor Antigens,Antigen, Tumor,Antigens, Tumor

Related Publications

R J Spence, and R M Simon, and A R Baker
The combined effect of radiotherapy and neuraminidase-treated tumor cells on 3-methylcholanthrene-induced fibrosarcoma.
January 1977, Journal of surgical oncology,
R J Spence, and R M Simon, and A R Baker
Comparative effect of Mycobacterium bovis- and neuraminidase-treated tumor cells on the growth of established methylcholanthrene fibrosarcomas in syngeneic mice.
January 1972, Cancer research,
R J Spence, and R M Simon, and A R Baker
Inhibition of cell-mediated cytotoxicity against tumor-associated antigens by suppressor lymph node cells from mice bearing methylcholanthrene-induced sarcomas.
January 1979, Neoplasma,
R J Spence, and R M Simon, and A R Baker
Non T suppressor cells in the lymph nodes of mice bearing methylcholanthrene-induced sarcomas.
January 1981, Folia biologica,
R J Spence, and R M Simon, and A R Baker
6-Mercaptopurine-induced potentiation of active immunotherapy in L1210-bearing mice treated with concanavalin A-bound leukemia cell vaccine.
February 1984, Cancer research,
R J Spence, and R M Simon, and A R Baker
Immunospecific regression of methylcholanthrene fibrosarcoma using neuraminidase. 3. Synergistic effect of BCG and neuraminidase treated tumor cells.
August 1972, Annals of surgery,
R J Spence, and R M Simon, and A R Baker
Distribution of radiolabeled alloantibodies in mice bearing 3-methylcholanthrene-induced sarcoma.
September 1979, Cancer research,
R J Spence, and R M Simon, and A R Baker
Immunotherapy of established micrometastases with Bacillus Calmette-Guérin tumor cell vaccine.
January 1978, Cancer research,
R J Spence, and R M Simon, and A R Baker
Immunotherapy with neuraminidase-treated tumor cells after radiotherapy.
December 1975, Radiation research,
R J Spence, and R M Simon, and A R Baker
Experimental cancer immunotherapy using a neuraminidase-treated non-viable frozen tumor vaccine.
April 1974, Surgery,
Copied contents to your clipboard!